Table 3 Outcomes by Trimester of Vaccination
From: Safety of SARS-CoV-2 vaccination during pregnancy- obstetric outcomes from a large cohort study
Outcome | Second Trimester n = 964 | Third Trimester n = 1329 | Unvaccinated n = 3313 | p |
|---|---|---|---|---|
Primary Outcomes | ||||
Preterm birth | 78 (8.1) | 40 (3.0) | 204 (6.2) | < 0.001 |
Small for gestational age | 58 (6.0) | 82 (6.2) | 233 (7.0) | 0.39 |
Secondary outcomes | ||||
Gestational age at delivery, weeks | 39.4 (38.4, 40.3) | 39.9 (38.6, 40.6) | 39.7 (38.7, 40.4) | 0.0012 |
Cesarean delivery | 159 (16.5) | 198 (14.9) | 529 (16.0) | 0.54 |
Postpartum hemorrhage (> 500 mL) | 35 (3.6) | 43 (3.2) | 104 (3.1) | 0.75 |
Intrauterine fetal demise | 10 (1.0) | 4 (0.3) | 33 (1.0) | 0.05 |
Birthweight, g | 3250 (2930, 3560) | 3315 (3000, 3618) | 3260 (2955, 3575) | 0.0012 |
Apgar 5 min | 10 (10, 10) | 10 (10, 10) | 10 (10,10) | 0.29 |
5 min Apgar < 7 | 16 (1.7) | 20 (1.5) | 63 (1.9) | 0.63 |
Umbilical arterial pH | 7.28 (7.21, 7.35) | 7.28 (7.21, 7.34) | 7.28 (7.22, 7.34) | 0.37 |
Umbilical pH < 7.1 | 46 (9.1) | 42 (6.0) | 122 (6.8) | 0.10 |
Umbilical arterial base excess | -4.3 (-6.2, -2.9) | -4.0 (-5.9, -2.5) | -3.9 (-5.7, -2.5) | 0.0054 |
Hypertensive disorder of pregnancy | 8 (0.8) | 16 (1.2) | 44 (1.3) | 0.46 |
Gestational diabetes | 104 (10.8) | 116 (8.7) | 275 (8.3) | 0.06 |